Immunome, Inc. (IMNM)

Immunome's stock price has experienced significant movements over the past six months, with a 159.21% increase in share price over the past year. Key events include positive topline results for the Phase 3 RINGSIDE trial of varegacestat in December 2025, a financing round raising $432.4 million, an upsized underwritten public offering generating $172.5 million in January 2026, and a biotech-focused fund adding $12 million to its Immunome investment in February 2026. In March 2026, Immunome reported its full-year 2025 financial results, with a net loss of $212.4 million. In April 2026, Immunome announced the submission of an NDA to the FDA for varegacestat and data from the Phase 3 RINGSIDE trial was selected for oral presentation at the 2026 ASCO Annual Meeting. In May 2026, Immunome is expected to report Q1 2026 results.

While a seasonal chart analysis for Immunome, Inc. exists, it is noted that only 5 years of data are available, which may be insufficient to create a reliable seasonal profile. The analysis suggests a period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. A "Buy Date" of June 20 and a "Sell Date" of September 30 has historically resulted in a geometric average return of 37.83% above the S&P 500 Total Return Index over the past 5 years. The demand for Immunome's products and services is primarily driven by unmet medical needs and the success of its clinical development programs rather than typical consumer seasonality.

Immunome, Inc. is a clinical-stage biotechnology company focused on targeted oncology, developing first-in-class and best-in-class cancer therapies. The company's strategy centers on targeted therapies addressing specific molecular drivers of cancer, leveraging experience in designing, developing, and commercializing targeted cancer therapies, including antibody-drug conjugates (ADCs). Key products include Varegacestat, an oral gamma secretase inhibitor in late-stage clinical development for desmoid tumors with a NDA submitted to the FDA in Q2 2026; IM-1021, a ROR1-targeted ADC in Phase 1 trial for B-cell lymphoma; IM-3050, a FAP-targeted radioligand therapy with a Phase 1 trial planned for early 2026; and a preclinical ADC pipeline including IM-1617, IM-1340, and IM-1335.

Immunome, Inc. is headquartered in Bothell, Washington, United States. The company's clinical trials, such as the Phase 3 RINGSIDE trial for varegacestat, are global in scope.

Immunome's brand reputation over the past year appears to be largely positive, driven by its clinical advancements and investor confidence. The company's focus on innovative therapeutic solutions in oncology and infectious diseases, coupled with a robust financial position, contributes to a favorable perception. Analysts maintain a strong conviction on the stock, with all 13 analysts covering Immunome rating it a "strong buy". Positive topline results from the Phase 3 RINGSIDE trial and the subsequent NDA submission for varegacestat have generated renewed investor optimism.

Immunome's ownership structure is characterized by a significant presence of institutional investors, holding approximately 35.36% to 80% of the company's stock. Insiders own approximately 1.62% to 4.75% of the company's stock. Public companies and retail investors hold a notable portion, with estimates around 12.55% to 47.34%.